Bioxyne secures $50M German cannabis deal

Bioxyne (ASX:BXN) announced a major $50 million exclusive supply agreement with German pharmaceutical giant ADREXpharma.

Facilitated through Bioxyne’s wholly owned subsidiary, Breathe Life Sciences, the two-year contract marks an expansion into Germany, currently Europe’s largest and most developed medicinal cannabis market.

The agreement centres on the distribution of BLS’s premium, Australian GMP-manufactured cannabis flower and associated products, providing a robust sales pathway into the heart of the European Union.

The financial structure of the deal offers substantial near-term revenue visibility for the company.

It includes an initial $25 million minimum commitment within the first 12 months, featuring an automatic renewal clause for a further 12 months to reach the total $50 million valuation.

As part of the strategic partnership, Adrex has been granted exclusive German distribution rights for the proprietary Dr Watson brand.

The exclusivity is underpinned by the significant purchase commitments, ensuring targeted market penetration and brand loyalty in a highly competitive landscape.

This milestone follows an initial agreement executed in June 2025, reflecting a rapidly increasing demand for high-quality, GMP-certified medicinal products across Europe.

At the time of reporting, Bioxyne's share price was $0.083.